** Shares of Abbott Laboratories ABT.N fall 2.85% to $126.19
** A judge in the Whitfield infant formula case granted a retrial to the plaintiffs following the October 31, 2024 verdict that handed a unanimous win in favor of Abbott and Reckitt's RKT.L unit Mead Johnson
** The ruling found the companies were not liable for failing to warn of the risks around necrotizing enterocolitis $(NEC.AU)$ in their infant formula products
** Today's ruling marks a setback following what seemed like a step in the right direction - J.P.Morgan
** ABT shares up ~8% in the last 12 months
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.